GGrantIndex
← Leaderboards

Robert W Schrier

University Of Colorado Denver

Google Scholar ↗PubMed ↗ORCID ↗
$16,805,433
Attributed
$16,805,433
Total exposure
13
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $3.8M · FY2005–14
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14

Funding mix

By agency

NIH$34,875,925 · 15

By mechanism

P01$20,708,676 · 7
U01$7,333,199 · 1
R01$6,582,305 · 2
M01$160,104 · 4
R56$91,641 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of Colorado Denver

Same institution · by research overlap

Others in their field

Top investigators on “Arginine Vasopressin”

Research focus

Arginine VasopressinPolycystic KidneyAutosomal Dominant TraitMagnetic Resonance ImagingHypertensionBlood PressureHormone Regulation /Control MechanismRenal FunctionKidneyHeart FailureAngiotensin-Converting Enzyme InhibitorsClinical ResearchCystic KidneyRandomizedClinical TrialsHuman SubjectLeft Ventricular MassEnd Stage Renal FailureExcretory FunctionGlomerular Filtration RateDesignLaboratory MouseHuman Therapy EvaluationAngiotensin /Renin /Aldosterone Hypertension

Grant awards (78)

Clinical Trial to Slow the Progression of ADPKD$89,230
U01 · FY2014 · DK · contact PI
Clinical Trial to Slow the Progression of ADPKD$733,144
U01 · FY2013 · DK · contact PI
Clinical Trial to Slow the Progression of ADPKD$783,144
U01 · FY2012 · DK · contact PI
Effect of Statin Therapy on Disease Progression in Children with ADPKD$43,741
R01 · FY2012 · DK · contact PI
Clinical Trial to Slow the Progression of ADPKD$783,144
U01 · FY2011 · DK · contact PI
Clinical Trial to Slow the Progression of ADPKD$783,144
U01 · FY2010 · DK · contact PI
Effect of Statin Therapy on Disease Progression in Children with ADPKD$765,000
R01 · FY2010 · DK · contact PI
Clinical Trial to Slow the Progression of ADPKD$812,219
U01 · FY2009 · DK · contact PI
Effect of Statin Therapy on Disease Progression in Children with ADPKD$569,019
R01 · FY2009 · DK · contact PI
Clinical Trial to Slow the Progression of ADPKD$300,816
U01 · FY2009 · DK · contact PI
Vasopressin and Hyperosmolality: Regulation, Adaptation$1,354,586
P01 · FY2008 · DK · contact PI
Clinical Trial to Slow the Progression of ADPKD$727,054
U01 · FY2008 · DK · contact PI
Effect of Statin Therapy on Disease Progression in Children with ADPKD$552,450
R01 · FY2008 · DK · contact PI
URINARY CONCENTRATING DEFECTS IN POLYDIPSIA AND HYPOTHYROIDISM$357,580
P01 · FY2008 · DK · contact PI
Vasopressin and Hyperosmolality: Regulation, Adaptation.$93,409
P01 · FY2008 · DK · contact PI
AGGRSSV RENIN-ANGIOTNSN-ALDOSTRN AXIS BLCKD IN PREVENT/SLOWING RENAL FNCTN DCLIN$12,893
M01 · FY2008 · RR · contact PI
Vasopressin and Hyperosmolality: Regulation, Adaptation$1,345,708
P01 · FY2007 · DK · contact PI
Effect of Statin Therapy on Disease Progression in Children with ADPKD$547,305
R01 · FY2007 · DK · contact PI
URINARY CONCENTRATING DEFECTS IN POLYDIPSIA AND HYPOTHYROIDISM$357,579
P01 · FY2007 · DK · contact PI
AGGRSSV RENIN-ANGIOTNSN-ALDOSTRN AXIS BLCKD IN PREVENT/SLOWING RENAL FNCTN DCLIN$109,738
M01 · FY2007 · RR · contact PI
Clinical Trial to Slow the Progression of ADPKD$109,600
U01 · FY2007 · DK · contact PI
Vasopressin and Hyperosmolality: Regulation, Adaptation.$93,695
P01 · FY2007 · DK · contact PI
Human Polycystic Kidney Disease$91,641
R56 · FY2007 · DK · contact PI
Vasopressin and Hyperosmolality: Regulation, Adaptation$1,348,378
P01 · FY2006 · DK · contact PI
Effect of Statin Therapy on Disease Progression in Children with ADPKD$547,231
R01 · FY2006 · DK · contact PI
Clinical Trial to Slow the Progression of ADPKD$400,000
U01 · FY2006 · DK · contact PI
URINARY CONCENTRATING DEFECT IN HYPOTHYROIDISM/ POLYDIPS$395,935
P01 · FY2006 · DK · contact PI
AGGRSSV RENIN-ANGIOTNSN-ALDOSTRN AXIS BLCKD IN PREVENT/SLOWING RENAL FNCTN DCLIN$5,261
M01 · FY2006 · RR · contact PI
Vasopressin and Hyperosmolality: Regulation, Adaptation$1,340,610
P01 · FY2005 · DK
Human Polycystic Kidney Disease$1,111,406
P01 · FY2005 · DK
URINARY CONCENTRATING DEFECT IN HYPOTHYROIDISM/ POLYDIPS$384,404
P01 · FY2005 · DK
ANTIHYPERTENSIVE THERAPY IN AUTOSOMAL DOMINANT PKD$374,245
R01 · FY2005 · DK
Pathogenesis of Endotoxemia-Induced Acute Renal Failure$292,765
R01 · FY2005 · DK
Clinical Trial to Slow the Progression of ADPKD$250,000
U01 · FY2005 · DK
Vasopressin and Hyperosmolality: Regulation, Adaptation$1,265,756
P01 · FY2004 · DK
Human Polycystic Kidney Disease$1,050,412
P01 · FY2004 · DK
Clinical Trial to Slow the Progression of ADPKD$600,000
U01 · FY2004 · DK
ANTIHYPERTENSIVE THERAPY IN AUTOSOMAL DOMINANT PKD$363,348
R01 · FY2004 · DK
URINARY CONCENTRATING DEFECT IN HYPOTHYROIDISM/ POLYDIPS$337,406
P01 · FY2004 · DK
Pathogenesis of Endotoxemia-Induced Acute Renal Failure$292,612
R01 · FY2004 · DK
REGULATION, RELEASE AND ACTION OF VASOPRESSIN$60,237
P01 · FY2004 · DK
REGULATION, RELEASE AND ACTION OF VASOPRESSIN$1,245,652
P01 · FY2003 · DK
Human Polycystic Kidney Disease$994,516
P01 · FY2003 · DK
Clinical Trial to Slow the Progression of ADPKD$491,244
U01 · FY2003 · DK
ANTIHYPERTENSIVE THERAPY IN AUTOSOMAL DOMINANT PKD$352,762
R01 · FY2003 · DK
Pathogenesis of Endotoxemia-Induced Acute Renal Failure$290,626
R01 · FY2003 · DK
REGULATION, RELEASE AND ACTION OF VASOPRESSIN$29,025
P01 · FY2003 · DK
REGULATION, RELEASE AND ACTION OF VASOPRESSIN$1,211,071
P01 · FY2002 · DK
Human Polycystic Kidney Disease$953,461
P01 · FY2002 · DK
Pathogenesis of Endotoxemia-Induced Acute Renal Failure$355,213
R01 · FY2002 · DK
ANTIHYPERTENSIVE THERAPY IN AUTOSOMAL DOMINANT PKD$342,488
R01 · FY2002 · DK
Clinical Trial to Slow the Progression of ADPKD$250,000
U01 · FY2002 · DK
Clinical Trial to Slow the Progression of ADPKD$220,460
U01 · FY2002 · DK
REGULATION, RELEASE AND ACTION OF VASOPRESSIN$81,125
P01 · FY2002 · DK
PROXIMAL TUBULE INJURY--PATHOGENESIS$75,274
R01 · FY2002 · DK
REGULATION, RELEASE AND ACTION OF VASOPRESSIN$28,537
P01 · FY2002 · DK
Core--Data Management and Statistical Facility$0
P01 · FY2002 · DK
REGULATION, RELEASE AND ACTION OF VASOPRESSIN$1,177,501
P01 · FY2001 · DK
Human Polycystic Kidney Disease$923,157
P01 · FY2001 · DK
ANTIHYPERTENSIVE THERAPY IN AUTOSOMAL DOMINANT PKD$345,263
R01 · FY2001 · DK
HUMAN POLYCYSTIC KIDNEY DISEASE$320,324
P01 · FY2001 · DK
PROXIMAL TUBULE INJURY--PATHOGENESIS$239,976
R01 · FY2001 · DK
REGULATION, RELEASE AND ACTION OF VASOPRESSIN$69,460
P01 · FY2001 · DK
ARTERIAL VASODILATION IN PREGNANCY, CIRRHOSIS AND HIGH OUTPUT CARDIAC FAILURE$0
P01 · FY2001 · DK
ARTERIAL VASODILATION IN PREGNANCY, CIRRHOSIS AND HIGH OUTPUT CARDIAC FAILURE$0
P01 · FY2001 · DK
Core--Data Management and Statistical Facility$0
P01 · FY2001 · DK
HYPERTENSION IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE$0
P01 · FY2001 · DK
REGULATION, RELEASE AND ACTION OF VASOPRESSIN$1,144,646
P01 · FY2000 · DK
HUMAN POLYCYSTIC KIDNEY DISEASE$921,304
P01 · FY2000 · DK
PROXIMAL TUBULE INJURY--PATHOGENESIS$232,987
R01 · FY2000 · DK
ARTERIAL VASODILATION IN PREGNANCY, CIRRHOSIS AND HIGH OUTPUT CARDIAC FAILURE$219,178
P01 · FY2000 · DK
ARTERIAL VASODILATION IN PREGNANCY, CIRRHOSIS AND HIGH OUTPUT CARDIAC FAILURE$219,178
P01 · FY2000 · DK
HYPERTENSION IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE$179,820
P01 · FY2000 · DK
REGULATION, RELEASE AND ACTION OF VASOPRESSIN$69,460
P01 · FY2000 · DK
VPA 985 IN TREATMENT OF HYPONATREMIA &CHRONIC HEART FAILURE$32,212
M01 · FY2000 · RR
REGULATION, RELEASE AND ACTION OF VASOPRESSIN$24,160
P01 · FY2000 · DK
VPA 985 IN TREATMENT OF HYPONATREMIA &CHRONIC HEART FAILURE$0
M01 · FY2000 · RR
ARTERIAL VASODILATION IN PREGNANCY, CIRRHOSIS AND HIGH OUTPUT CARDIAC FAILURE$0
P01 · FY2000 · DK